Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05171855 · ClinicalTrials.gov registry record · Phase 3
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
A Phase 3 study, sponsored by Ascendis Pharma Endocrinology Division A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT05171855 is a Phase 3 study that has completed, run by Ascendis Pharma Endocrinology Division A/S. The registered enrollment target is 220 participants.
The verdict
NCT05171855, a Phase 3 study, has completed, sponsored by Ascendis Pharma Endocrinology Division A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period in study TCH-306 (foresiGHt; NCT04615273).
Interventions
- DRUG Lonapegsomatropin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2021-12-16 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05171855
The ClinicalTrials.gov registry entry for NCT05171855 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascendis Pharma Endocrinology Division A/S, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lonapegsomatropin is the first listed.
NCT05171855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05171855 about?
NCT05171855 is a clinical study titled "A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency". This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants were adults (males and females) with confirmed growth hormone deficiency (GHD) having completed the treatment period ...
What is the current status of trial NCT05171855?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2021-12-16. Estimated completion is 2024-12-23.
What interventions are being tested in trial NCT05171855?
The interventions under investigation include: Lonapegsomatropin (DRUG).
Who is sponsoring clinical trial NCT05171855?
This trial is sponsored by Ascendis Pharma Endocrinology Division A/S, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.